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Background. The guidelines on antithrombotic treatment in patients with symptomatic peripheral artery disease (PAD) undergoing
peripheral revascularization of the lower extremities were developed based on heterogeneous trials, assessing various dose regimens
and recruiting patients who were subjected to different revascularization procedures. Objective. To compare efficacy and safety of
treatments used in patients with PAD undergoing peripheral revascularization accounting for between-trial heterogeneity and large
dispersion of the quality of evidence. Methods. A systematic literature review of randomised controlled trials (RCTs) recruiting
adult patients with PAD receiving antithrombotics was conducted until January 2020. Hazard ratios (HR) were pooled using
Bayesian network meta-analysis. The estimated between-treatment effects were presented as HR together with 95% credible
intervals. The base case analysis included studies recruiting patients following recent peripheral revascularization, who received
treatment regimens administered within the recommended therapeutic window, while a sensitivity scenario included all
identified trials. Results. Thirteen RCTs were identified (8 RCTs enrolled patients following peripheral revascularization and 5
RCTs regardless of the previous revascularization). Five trials, recruiting an overall of 8349 patients, were considered for the
base case analysis. Of those, 6564 patients were recruited in the VOYAGER PAD trial comparing rivaroxaban plus aspirin (RIV
plus ASA) versus ASA. RIV plus ASA was associated with a lower risk of repeated peripheral revascularization versus ASA
monotherapy (HR = 0:88 [0.79, 0.99]), however having a trend towards an increased rate of major bleeding (HR = 1:43 [0.98,
2.11]). There was no evidence for differences between RIV plus ASA and dual antiplatelet therapy and vitamin K antagonists
plus ASA. Similar results were observed in sensitivity analyses. Conclusions. RIV plus ASA is associated with reduced risk of
revascularization compared with ASA monotherapy, but the evidence for other comparators, in particular antiplatelet regimens,
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1. Introduction
Peripheral artery disease (PAD) is a common cardiovascular
(CV) system disease with the global prevalence exceeding 200
million people and incidence of about 11 million in 2017 [1,
2]. Progressive atherosclerosis causes stenosis or occlusion of
peripheral arteries. Depending on the location and severity of
the stenosis, the disease is asymptomatic or symptomatic
with intermittent claudication (IC) or atypical leg pain, criti-
cal limb ischemia (CLI), and acute limb ischemia (ALI) as
typical signs [3–6]. CLI leads to chronic hypoperfusion
resulting in a substantial increase in the risk of limb loss
[7–9]. For this reason, patients with CLI or the occurrence
of lifestyle-limiting symptoms classified as being grade IIb
according to the Fontaine classification may require revascu-
larization of the lower extremity arteries [10, 11]. Revascular-
ization immediately improves quality of life in PAD patients
and improves long-term survival [12], although it is associ-
ated with a postprocedural increase of vascular risk [13].
The clinical trials on the antithrombotic medication dif-
fer noticeably in terms of quality and sample size, with lim-
ited evidence for the efficacy and safety of antiplatelet
medication used in patients who have undergone revascular-
ization, in particular for those after recent endovascular pro-
cedures [4]. Due to this reason, the recommendations of
practice guidelines were often developed based on low-
quality evidence [4]. A single antiplatelet therapy (SAPT)
with acetylsalicylic acid (ASA) or clopidogrel (CLO) alone
is recommended for all patients with symptomatic PAD
who have undergone revascularization to reduce the risk of
atherothrombotic events (Class I with level of evidence C).
Dual antiplatelet therapy (DAPT), consisting of low doses
of ASA in combination with a P2Y12 receptor antagonist, is
recommended for at least one month for patients following
endovascular procedures (Class IIa with level of evidence
C). DAPT with ASA plus CLO for at least 1 month can be
considered in patients undergoing bypass surgery with a
prosthetic graft (Class IIb with level of evidence B) [4].
Despite existing guidelines, a comparison of treatments for
PAD patients after peripheral revascularization encounters
difficulties mainly due to small population of PAD patients
enrolled in the studies and cooccurrence of PAD and coro-
nary artery disease. Additionally, different revascularization
procedures, including surgical and endovascular, were used
in respective trials. Of note, the available endovascular proce-
dures evolved over the years which additionally increase het-
erogeneity. Rivaroxaban (RIV), a selective direct inhibitor of
factor Xa, plus ASA is the most recent treatment option stud-
ied for PAD patients. Based on the COMPASS trial in
patients suffering from chronic coronary artery disease
and/or PAD, RIV plus ASA was included in the guidelines
as an antithrombotic therapy in lower extremity artery dis-
ease [4]. RIV plus ASA was also recently assessed in another
large clinical trial (VOYAGER PAD) in patients with symp-
tomatic PAD undergoing surgical or endovascular revascu-
larization [14]. In both studies, RIV plus ASA was
compared to ASA alone; there are no data comparing efficacy
and safety of RIV plus ASA with other therapies (e.g., clopi-
dogrel and VKA). Therefore, the objective of this analysis
was to review available evidence for treatments used in
patients with PAD undergoing peripheral revascularization
procedures of the lower extremities and conduct a network
meta-analysis (NMA) to estimate relative efficacy and safety.
2. Material and Methods
2.1. Systematic Literature Review. A systematic literature
review (SLR) was conducted to identify randomised con-
trolled trials (RCTs) on adult patients with acute symptom-
atic PAD, presenting the clinical evidence for the following
therapeutic options: RIV plus ASA, CLO plus ASA, ASA
monotherapy, CLO monotherapy, vitamin K antagonists
(VKAs) with or without ASA or CLO, and a placebo. The
search was conducted in January 2020 in MEDLINE, MED-
LINE In-Process, EMBASE, and CENTRAL. No timeframe
and geographical scope restrictions were imposed; however,
for conferences/congresses searches, only records issued
from 2015 on were considered. Inclusion criteria are sum-
marised in Table 1.
The selection of RCTs was conducted by 2 analysts work-
ing independently, and any disagreements between the 2
analysts were resolved by a third analyst. Data from studies
meeting all inclusion criteria were extracted by one analyst;
its quality was thoroughly checked by the second analyst.
The risk of bias was assessed for each study using the tool
developed by the Cochrane Collaboration [15].
2.2. Additional Criteria for Inclusion in the Network Meta-
Analysis. The intention of this analysis was to compare the
RIV plus ASA regimen with treatments recommended by
the current clinical practice guidelines to treat patients with
PAD after revascularization. We considered all RCTs asses-
sing antiplatelet therapies or anticoagulant treatment enroll-
ing patients with PAD of lower extremity with and without a
history of recent revascularization to increase the power of
this NMA [4–6]. Based on clinical practice guidelines, the fol-
lowing therapies were considered as comparators for RIV
plus ASA: ASA monotherapy, CLO monotherapy, CLO in
combination with ASA, VKA monotherapy, and VKA plus
ASA [4].
Treatments were compared regarding clinically relevant
outcomes reported across analysed studies [14]. Efficacy out-
comes included IS, any stroke, MI, CV death, coronary heart
death, all-cause death, major amputations (between-trial het-
erogeneity of definition), revascularization, venous thrombo-
embolism (VTE), and hospitalization. Major bleeding (MB)
was considered as a safety outcome; however, the definitions
of this event varied across studies (Supplementary Table 7).
Therefore, the comparison regarding major bleeding needs
to be interpreted with caution.
2.3. Data Synthesis. Two trials assessing RIV plus ASA in
patients with PAD were identified through the SLR [14,
16]. Both compared a combination of RIV plus ASA versus
ASA alone. There are no studies comparing efficacy and
safety of RIV-based treatment to other therapies mentioned
in the clinical guidelines. In 11 RCTs (BOA [17], CAPRIE
[18], CASPAR [19], Cassar 2005 [20], CHARISMA [21],
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COMPASS [16], Eikelboom 2005 [22], Johnson 2002&2004
[23], MIRROR [24], VOYAGER PAD [14], and WAVE
[25]), patients allocated to reference arms received ASA
monotherapy, and in 9 of those 11 trials, ASA was also
administered as a combination therapy in the second arm.
ASA monotherapy serves as a common reference treatment
in the majority of studies, thus forming a network of evidence
and allowing an indirect-treatment comparison using an
NMA.
An NMA in Bayesian framework was used to compare
RIV plus ASA versus other treatments [26]. The NMA is an
extension of traditional pairwise meta-analysis which uses
Markov chain Monte Carlo sampling to compare different
treatments assessed in different studies, if they form a con-
nected network of evidence.
The model inputs are natural logarithms of hazard ratio
(log(HR)) for between-treatment comparison and the corre-
sponding SE(log(HR)). When respective trials reported esti-
mates calculated after several interim analyses, only final
estimates corresponding to the longest available follow-up
were included for the NMA. Neither of the included trials
reported information suggesting violation of proportionality
of hazards. For studies not reporting HRs, they were esti-
mated by fitting the exponential survival curve to the
reported number of events.
Three chains were initiated with noninformative priors
and run in parallel for each analysis. The convergence
between chains was checked using the Brooks-Gelman-
Rubin diagnostic and trace plots. There were no closed loops
in the evidence networks; thus, there was no reason for the
analysis of consistency.
The NMA was conducted using fixed- and random-effect
models with deviance information criterion (DIC) as the
indicator of model fit to clinical data. The fixed-effect model
was preferred; however, the random-effect model was con-
sidered relevant when associated with DIC value lower by
≥5 points [27]. The results are presented as HR together with
corresponding 95% credible intervals (95% CI). Ranking
probabilities of all treatments used the surface under the
cumulative ranking area (SUCRA).
3. Results
3.1. SLR Results.Overall, 14 RCTs were identified, including a
small, phase II study (RIVAL PAD [28]), which did not
report any events relevant for this analysis and thus was
finally excluded from the NMA. Therefore, a total of 13 RCTs
were considered relevant for inclusion in the NMA (Supple-
mentary Table 1). Of those, 8 RCTs (VOYAGER PAD [14],
BOA [17], CASPAR [19], Johnson 2002&2004 [23], Cassar
2005 [20], Li 2013 [29], MIRROR [24], and Liang 2012
[30]) recruited patients following peripheral
revascularization procedures of the lower extremities. Three
studies (BOA [17], CASPAR [19], and Johnson 2002&2004
[23]) assessed patients after recent surgical procedures, four
(Cassar 2005 [20], Li 2013 [29], MIRROR [24], and Liang
2012 [30]) recruited participants who have undergone
endovascular procedures, and one (VOYAGER PAD)
recruited a large sample representative for patients who
have undergone either surgical or endovascular procedures.
The remaining 5 studies (CAPRIE [18], COMPASS [16],
CHARISMA [21], Eikelboom 2005 [22], and WAVE [25])
enrolled patients with a diagnosis of PAD regardless of
previous revascularization (Table 2). Figure 1 shows a
distribution of clinical trials according to the history and
type of revascularization.
Input data for the NMA is presented in Supplementary
Tables 1–8. Identified studies differed in terms of
Table 1: Inclusion criteria for the systematic literature review according to PICOS methodology.
PICOS Inclusion criteria









Efficacy including the following:
ALI, major amputation, MI, IS, CV death
Hospitalization for a coronary or peripheral cause (either lower limb) of a thrombotic nature
All-cause death
Safety including the following:








AE: adverse event; ALI: acute limb ischemia; ASA: aspirin; CLO: clopidogrel; CV: cardiovascular; IS: ischemic stroke; MI: myocardial infarction; PAD:
peripheral artery disease; RCT: randomised controlled trial; VKA: vitamin K antagonists.
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Table 2: Characteristics of eligible studies on PAD patients meeting inclusion criteria for NMA.













6564 100% (recent)∗ Double blind Median: 28








Open label Mean: 21
CASPAR (2010) [19] CLO+ASA (75-100mg)
ASA
(75-100mg)






831 Open label Mean: 36.6
PAD after revascularization: endovascular






Li 2013 [29] CLO+warfarin (INR 1.8-2.5) CLO 88 Open label ≤12
MIRROR (2012) [24] CLO+ASA (100mg)
ASA
(100mg)
80 Double blind 6
Liang 2012 [30] CLO+warfarin (INR 1.8-2.5) CLO 56 Open label ≤12
Chronic PAD patients





Not reported Double blind Mean: 22.9
COMPASS (2017) [16]




27.4% Double blind Mean: 23
RIV (5mg bid)





50.6% Double blind Median: 28
Eikelboom (2005) [22] CLO+ASA (100mg)
ASA
(100mg)






2161 Not reported Open label Mean: 35
AE: adverse event; ALI: acute limb ischemia; ASA: aspirin; bid: twice a day; CLO: clopidogrel; CV: cardiovascular; INR: international normalised ratio; IS:
ischemic stroke; MI: myocardial infarction; NMA: network meta-analysis; PAD: peripheral artery disease; pt-yrs: patient-years; RCT: randomised controlled























Figure 1: Distribution of clinical trials according to the history and type of revascularization.
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methodological quality, of population characteristics, of
procedure types, of follow-up duration, of ASA doses, of
history of previous revascularization procedure, and of
concomitant CAD and differed regarding major bleeding
definition (Supplementary Table 7) and additional
treatments contributing to between-trial heterogeneity
(Table 2). Moreover, in the light of the rapid development
of technologies for endovascular revascularization, all the
identified studies assessing P2Y12 receptor antagonist in
this group of patients, which were published between 2005
and 2013, may not be representative for the contemporary
procedures.
3.1.1. Risk of Bias. The risk of bias was evaluated for all
included trials and summarised in Supplementary Table 1.
There was no evidence for the risk of bias arising from the
randomisation, although Li 2013 did not disclose all
necessary details of the randomisation process. All trials
comparing different antiplatelet regimens were conducted
in a double-blinded fashion, while studies assessing
anticoagulation were open label, which is justified given the
need for close monitoring of INR in patients receiving
VKA. Baseline characteristics were generally well balanced
between the study groups; in some studies, there were
differences however with no statistically significant
interaction with the reported results. There was a higher
proportion of patients with a history of coronary artery
disease and/or cerebrovascular disease in the CLO
treatment arm in the CASPAR trial and a higher
proportion of patients with coronary artery disease in the
antiplatelet arm in the WAVE trial.
3.1.2. Population. Eleven out of 13 clinical trials enrolled just
patients with lower extremity PAD; however, the protocols of
2 RCTs (COMPASS [16]; WAVE [25]) allowed also the
inclusion of patients with carotid artery disease.
As mentioned before, the included trials differed regard-
ing a history of the previous revascularization, type of proce-
dures, etc. Eight out of the 13 RCTs were designed to assess
therapeutic effects following recent peripheral revasculariza-
tion. They recruited patients who recently underwent revas-
cularization using either surgical (4 RCTs: VOYAGER PAD
[14], BOA, CASPAR [19], and Johnson 2002&2004 [23]) or
endovascular procedures (5 RCTs: VOYAGER PAD [14],
CASSAR, Li 2013 [29], MIRROR [24], and Liang 2012
[30]) or hybrid procedure (VOYAGER). Studies just includ-
ing PAD patients after a recent endovascular revasculariza-
tion were small, with the number of recruited patients
ranging from 56 to 132. The VOYAGER PAD trial [14]
assessed RIV plus ASA in patients after surgical and/or endo-
vascular procedures. The randomisation in this trial was
stratified by procedure type and CLO use into surgical revas-
cularization and endovascular procedures with or without
concomitant CLO; hybrid procedure was considered as
endovascular procedure.
Six trials (VOYAGER PAD [14], BOA [17], CASPAR
[19], Cassar 2005 [20], MIRROR [24], and Li 2013 [29]) pro-
vided the number of days, within which the treatment was
initiated after the revascularization. In general, the first dose
of the investigated treatment was administered within 10
days after the procedure. In one RCT (Johnson 2002&2004
[23]), the treatment with warfarin was administered as soon
as patients tolerated oral fluids. The remaining trial (Li
2012) stated that the treatment was initiated following
angioplasty.
The 5 remaining trials (WAVE [25], CAPRIE [18],
COMPASS [16], CHARISMA [21], and Eikelboom 2005
[22]) recruited patients with chronic PAD. These trials
allowed to include patients with or without a history of
peripheral revascularization. Prior procedure was not
required for enrolment, and the time since revascularization
was quite inconsistent. Three (COMPASS [16], CHARISMA
[16], and Eikelboom 2005 [22]) out of these 5 RCTs recruit-
ing patients with chronic PAD reported history of peripheral
revascularization with a range of 27% to 58% (Table 2).
3.1.3. Interventions and Comparators. Out of the 5 RCTs
(BOA [17], Johnson 2002&2004 [23], Li 2013 [29], and Liang
2012 [30]) assessing VKA-based regimens in 2 RCTs (BOA
[17]; WAVE [25]), the target INR was 2.0-3.0 and 3.0 to
4.5, respectively. In 11 RCTs (BOA [17], CAPRIE [18], CAS-
PAR [19], Cassar 2005 [20], CHARISMA [21], COMPASS
[16], Eikelboom 2005 [22], Johnson 2002&2004 [23], MIR-
ROR [24], VOYAGER PAD [14], and WAVE [25]), patients
allocated to the reference arm received either ASA mono-
therapy and/or ASA combined with other treatments. There
was between-trial heterogeneity regarding ASA doses. A high
ASA daily dose (325mg) was administered in 2 trials
(CAPRIE [18], Johnson 2002&2004 [23]); a broad range of
ASA daily doses (81-325mg) was allowed in the WAVE trial
[25]; and low ASA dose (≤100mg) was administered in the
remaining trials.
In the WAVE trial [25], around 7% of participants
received concomitant thienopyridines in either group, which
further increased the level of heterogeneity associated with
the assessed treatments. There was no analysis stratified by
clopidogrel use in the WAVE trial that could assess the
potential impact of thienopyridine use on the efficacy and
safety results. Similarly, patients assigned to endovascular
procedures of the VOYAGER PAD trial were stratified
according to clopidogrel use (endovascular procedure with
or without clopidogrel), but finally, no significant interaction
between clopidogrel use and the outcomes was observed,
between-trial heterogeneity.
The analysis of heterogeneity revealed noticeable
between-trial differences, which could potentially interact
with the estimates of the treatment effects and bias the infer-
ence based on the results of the NMA. The most important
sources of heterogeneity were rooted in population differ-
ences, in procedure differences, e.g., different ASA doses
and different treatment strategies. Due to the between-trial
heterogeneity, two variants of the analysis were chosen.
(1) Base Case. The aim of this analysis was to assess between-
treatment differences in efficacy and safety based on RCTs
with a high level of homogeneity regarding the target popula-
tion and assessing treatment regimens administered in accor-
dance with clinical practice guidelines [4]. Therefore, this
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analysis was conducted only on studies recruiting patients
following recent revascularization, who received treatment
regimens administered within the recommended therapeutic
doses.
There was limited number of studies meeting the inclu-
sion criteria for the base case analysis; thus, the comparison
with some of the predefined comparators including VKA
monotherapy, CLO monotherapy, and the combination
treatment including CLO plus ASA was not feasible.
(2) Sensitivity Analysis. The aim of this analysis was to allow
for the comparison versus comparators not assessed in the
base case and analyse the robustness of the comparative
results based on relaxed inclusion/exclusion criteria while
acknowledging the heterogeneity introduced with that. This
analysis was conducted based on the 13 studies included in
the NMA.
3.2. Results of the NMA
3.2.1. Base Case Analysis. Fixed-effect models were consid-
ered for each comparison based on DIC criterion and consid-
ering that in most cases only one study was available for each
comparison; therefore, the heterogeneity parameter could
not be estimated. A consistency analysis was not conducted
as all the networks had star-like shape without closed loops
allowing to compare between direct and indirect evidence.
The trials eligible for the base case analysis allowed to
form a network of evidence linking RIV plus ASA (VOY-
AGER PAD) with CLO plus ASA (CASPAR, Cassar 2005,
MIRROR) and VKA plus ASA (Johnson 2002&2004)
through ASA monotherapy. RIV plus ASA and CLO plus
ASA could formally be compared regarding all outcomes of
interest except for ALI, which was assessed only in the VOY-
AGER PAD trial [14]. On the contrary, the Johnson et al.’s
trial (Johnson 2002&2004) [23] which compared VKA plus
ASA and ASA reported only all-cause death, any stroke,
MI, and major bleeding; therefore, the comparison was lim-
ited to reported outcomes.
Consistent with the results of the VOYAGER PAD trial
[14], this analysis showed that RIV plus ASA compared with
ASA monotherapy is associated with a significantly lower
risk of unplanned index-limb revascularization for recurrent
ischemia. The comparison between RIV plus ASA with
DAPT (CLO plus ASA) and warfarin-based regimen did
not reveal any significant differences between treatments
regarding safety and efficacy outcomes. However, a trend in
favour of RIV plus ASA was observed for comparison with
VKA plus ASA regarding all-cause deaths (HR = 0:77 [0.57,
1.04]) (Table 3).
3.2.2. Sensitivity Analysis. Additional trials included in the
sensitivity analysis allowed for the assessment of relative
treatment effects also versus CLO monotherapy and VKA
monotherapy, although the former option was only the com-
parison for CV deaths, IS, any stroke, and the risk of MI.
Consistent with the base case analysis, RIV plus ASA was
associated with a lower risk of peripheral revascularization
compared with ASA monotherapy (HR = 0:89 [0.81, 0.98]).
For the majority of the remaining outcomes, there was no
significant difference between RIV plus ASA and ASA except
for the risk of major bleeding, which was significantly higher
in the RIV plus ASA group (HR = 1:52 [1.17, 1.98]) com-
pared to ASA alone.
The NMA did not reveal significant treatment differ-
ences, with the exception for the comparison with VKA plus
ASA regarding major bleeding; there was a lower risk associ-
ated with RIV plus ASA (HR = 0:54 [0.33, 0.89]).
The inclusion of additional studies enrolling stable popu-
lation leads to a nonsignificant modification of the relative
effects. The results of the CHARISMA trial [21] favoured
CLO plus ASA over ASA regarding all-cause death, CV
death, and major bleeding; thus, the point estimates for com-
parison between RIV plus ASA versus CLO plus ASA
favoured the latter treatment regarding these outcomes,
although all estimates were not significant.
There were no other major differences in the direction
and significance of the effect estimates between the base case
scenario and the sensitivity analysis, which could modify the
inference.
Input data on amputations for the NMAs are presented
in Table 4. Input data on other outcomes for the NMAs (Sup-
plementary Tables 1–8), figures presenting networks of
evidence for all outcomes (Supplementary Figures 1, 3, 5, 7,
9, 11, 13, and 15), and forest plots (Supplementary
Figures 2, 4, 6, 8, 10, 12, 14, and 16) are presented in
Supplementary Materials. The results of the base case
scenario and sensitivity analysis are shown in Table 3.
4. Discussion
With this NMA, we attempted to summarise existing evi-
dence on efficacy and safety profiles of treatments used in
patients with PAD undergoing peripheral revascularization
and accounting for the between-trial heterogeneity and large
dispersion of the quality of evidence.
The SLR conducted to collect data for the NMA revealed
scarcity and serious limitations of available clinical data. We
identified only 5 RCTs reporting adequate results that were
eligible for the base case analysis and allowed to compare
RIV plus ASA only with 2 regimens: CLO plus ASA and
VKA plus ASA. Of those, the VOYAGER PAD study was
the largest trial enrolling 6564 out of 8449 patients recruited
in all studies included for the base case scenario. The study
was designed and powered to compare RIV plus ASA versus
ASA in a double-blinded fashion regarding clinically relevant
outcomes and showed a significant reduction of the primary
efficacy endpoint defined as a composite of acute limb ische-
mia, major amputation for vascular causes, myocardial
infarction, ischemic stroke, or death from cardiovascular
causes. All participants underwent a recent peripheral revas-
cularization prior to a random allocation to treatment
groups, which was stratified according to the type of revascu-
larization procedure (endovascular (including hybrid) vs.
surgical) and according to clopidogrel use among those
who underwent an endovascular procedure [14]. The pri-




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































composite endpoint, and several secondary outcomes were
tested in a hierarchical order. The principal safety outcome
was major bleeding according to the Thrombolysis in Myo-
cardial Infarction (TIMI) classification. The results of the
VOYAGER PAD trial showed that RIV plus ASA reduced
the risk of the primary efficacy outcome by 15% compared
with ASA monotherapy (HR = 0:85 [0.76, 0.96]; p = 0:009)
with no significant increase of the rate of TIMI major bleed-
ing (HR = 1:43 [0.97, 2.10]; p = 0:07) and a significant
increase in ISTH major bleeding events (HR = 1:42 [1.10,
1.84]; p = 0:007).
While the large VOYAGER study provided high-quality
results for assessing the clinical effectiveness of RIV plus
ASA, the evidence for other therapeutic options in a postre-
vascularization setting is limited. ASA and ASA plus CLO
were compared in patients after endovascular procedures in
only 2 RCTs (Cassar 2005 [20]; MIRROR [24]) recruiting
103 and 68 patients, respectively. Both RCTs were designed
to assess platelet functions and had inadequate power for
the evaluating clinically relevant outcomes. Moreover, both
studies were conducted before 2012 and thus may not repre-
sent the contemporary endovascular procedures, which
evolved in the recent years.
One trial (CASPAR [19]) compared CLO plus ASA versus
ASA monotherapy in 851 patients following surgical revascu-
larization. This study did not demonstrate a benefit of CLO
plus ASA over ASA regarding the primary endpoint, defined
as a composite of index-graft occlusion or revascularization,
above-ankle amputation of the affected limb, or death
(HR = 0:98 [0.78-1.23]). A post hoc analysis in the subset of
patients with prosthetic grafts showed a difference in favour
of the CLO plus ASA regimen (HR = 0:65 [0.45-0.95]).
Finally, the remaining trial included in the base case compared
VKA plus ASA versus ASA in 831 PAD patients after a surgi-
cal revascularization. The study was designed to assess graft
patency and mortality. The results indicated that a combina-
tion of VKA plus ASA is associated with increased mortality
(HR = 1:41 [1.09, 1.84]) and elevated risk of major bleeding
(p = 0:02) including intracranial bleed, hospitalization for
bleeding, an operation for control of bleeding, or a blood
transfusion. Neither of the trials identified through an SLR
provided clinical evidence for the efficacy of CLO monother-
apy in patients following revascularization; thus, the evidence
supporting the use in that population is questionable.
This NMA suggests that RIV in combination with ASA is
associated with reduced risk of peripheral revascularization
compared with ASA monotherapy, but there seems to be no
differences between RIV plus ASA and other treatment
options. However, such an indirect comparison has major lim-
itation due to the high heterogeneity of the included trials. The
sensitivity analysis with broader inclusion criteria, but with an
even more increased heterogeneity, came to the same result.
With one exception, the inclusion of additional trials led to
an increased estimate of the risk of major bleeding in the
VKA plus ASA group compared with RIV plus ASA. The
results of this NMA were still imprecise since not all studies
included in the network were of sufficient quality and power
to draw reliable conclusions based on indirect treatment com-
parison. Included trials were not powered for the assessment
of the individual clinical outcomes but were designed to assess
either composite outcomes or surrogates. The results of the
sensitivity analysis were associated with high uncertainty due
to associated between-trial heterogeneity. Therefore, although
this NMA was conducted in accordance with the highest
methodological principles, the available clinical evidence is
insufficient to draw reliable conclusions regarding the relative
effectiveness and safety of the therapies used in patients after
revascularization of peripheral arteries.
The main limitations of the identified scientific evidence
are the inadequate samples of included trials and the related
insufficient statistical power to assess respective clinically rel-
evant outcomes. In addition, this NMA with a star-like evi-
dence network inherited the limitations from the individual
pairwise comparisons, which means that the quality of the
Table 4: Input data for the NMA of the risk of amputation.
Study Treatments
Event rate




CLO+ASA 6/35 (17.1%) 0.94 [0.30, 2.91]
✔ ✔
ASA 6/33 (18.2%) Reference
CASPAR [19]
CLO+ASA 31/425 (7.3%) 0.68 [0.43, 1.08]
✔ ✔
ASA 45/426 (10.6%) Reference
VOYAGER PAD [14]
RIV+ASA 103/3286 (3.1%) 0.89 [0.68, 1.16]
✔ ✔
ASA 115/3278 (3.5%) Reference
BOA [17]
VKA 100/1326 (7.5%) 0.90 [0.69, 1.19]
✗ ✔
ASA 110/1324 (8.3%) Reference
CHARISMA [21]
CLO+ASA 12/1545 (0.8%) 0.71 [0.34, 1.48]
❌ ✔
ASA 17/1551 (1.1%) Reference
COMPASS [16]
RIV+ASA 20/2492 (0.8%) 0.53 [0.31, 0.91]
❌ ✔
ASA 38/2504 (1.5%) Reference
WAVE [25]
VKA+ASA 8/1080 (0.7%) 0.67 [0.27, 1.63]
❌ ✔
ASA 12/1081 (1.1%) Reference
✔: study eligible for the analysis; ❌: study ineligible for the analysis. ASA: acetylsalicylic acid; CLO: clopidogrel; RIV: rivaroxaban; VKA: vitamin K antagonist.
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comparison between RIV plus ASA and comparators is lim-
ited by the quality of evidence for comparators. Thus, small
trials on comparators, not always designed to assess clinically
relevant outcomes, are insufficient to draw reliable conclu-
sions regarding relative efficacy and safety between the treat-
ments used in clinical practice in this target population. The
low power of this analysis and the between-trial heterogene-
ity with high probability explains the lack of significant dif-
ferences between treatments assessed within this NMA. The
definition of major bleeding was heterogeneous across
included studies (Supplementary Table 7), although there
was no evidence that the definition of major bleeding
events could affect the relative difference between groups
expressed with hazard ratios. Moreover, the risk of bleeding
is expected to increase with the dose/number of antiplatelet
therapies and the intensity of anticoagulation treatments.
Since the daily dose of ASA ranged from 75mg to 325mg
and the target INR also differed across studies assessing
anticoagulation, the between-treatment differences
regarding the risk of major bleeding should be interpreted
with adequate caution. Despite including additional studies,
the sensitivity analysis also did not allow a reliable and
unequivocal conclusion regarding treatment differences and
did not noticeably change the results of the primary analysis.
In summary, the results of this NMA are considered
imprecise due to the low power of some of the included trials
to assess relevant clinical outcomes and due to the high
between-trial heterogeneity. Therefore, although this NMA
was conducted in accordance with high methodological prin-
ciples, no reliable conclusions regarding efficacy and safety of
therapies in symptomatic PAD patients after a recent revascu-
larization can be drawn. To assess clinical efficacy and safety
of, for example, clopidogrel or other anticoagulant therapies
in such a population, well-powered, randomised double-
blind clinical studies like the VOYAGER trial are required.
5. Conclusions
There was limited clinical evidence for the therapies used in
the treatment of patients with PAD undergoing peripheral
revascularization procedures of the lower extremities. Of
these, RIV plus ASA was assessed in the largest clinical pro-
gram on over 11,500 patients with PAD, of which 6564 were
enrolled following recent peripheral revascularization. This
analysis suggests that RIV in combination with ASA is asso-
ciated with reduced risk of revascularization compared with
ASA monotherapy, but the evidence for comparators was
insufficient to improve treatment decisions and highlights
the challenge in establishing the magnitude of comparative
treatment effects using existing RCT data. Robust evaluation
of clinical outcomes may therefore require extending the
scope of the evaluation beyond RCT data.
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file.
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